Safety of trovafloxacin in treatment of lower respiratory tract infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 454-458

  Williams, D ^a   Hopkins, S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENSORY DYSFUNCTION; URINARY TRACT DISEASE; VERTIGO;

EID: 0031753351     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691582     Document Type: Article

References (24)

1. Pechère J-C: Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17: 405-412
2. Edelstein PH, Edelstein MAC, Ren J, Polzer R, Gladue RP: Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy (1996) 40:314-319
3. Vincent J, Teng R, Dogolo L, Baris BA, Willavize SA: Single-and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in man. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:427-430
4. Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer SJ, Friedman HL: Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 75-80
5. Fischman AJ, Babich JW, Alpert NM, Vincent J, Wilkinson RA, Callaghan RJ, Correia JA, Rubin RH: Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coliinfected rats and rabbits studied with positron emission tomography. Clinical Microbiology and Infection (1997) 3:63-71
6. Andrews JM, Honeybourne D, Brenwald NP, Bannerjee D, Iredale M, Cunningham D, Wise R: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 797-802
7. Hooper DC, Wolfson JS: Adverse effects. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents. American Society for Microbiology, Washington DC (1993) pp. 489-512
8. Jüngst G, Mohr R: Overview of postmarketing experience with ofloxacin in Germany. Journal of Antimicrobial Chemotherapy (1988) 22, Supplement C: 167-175
9. Reiter C, Pfeiffer M, Hullman N: Brief report: safety of ciprofloxacin based on phase IV ("Anwendungsbeobachtung") in the Federal Republic of Germany. American Journal of Medicine (1989) 87, Supplement A: 103-106
10. Haria M, Lamb HM: Trovafloxacin. Drugs (1997) 54:435-445
11. O'Doherty B, Daniel R, the Trovafloxacin Bronchitis Study Group: Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:441-446
12. Léophonte P, Baldwin RJT, Pluck N: Trovafloxacin versus amoxicillin/clavulanic acid treatment of acute exacerbations of chronic bronchitis. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:434-440
13. Trémolières F, de Kock F, Pluck N: Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:447-453
14. Carbon C, Rubinstein E (eds) Sparfloxacin monograph. Adis International (1994) Chester, p. 45
15. Rizk E: The US clinical experience with lomefloxacin, a new once-daily fluoroquinolone. American Journal of Medicine (1992) 92, Supplement 4A: 130-135
16. Gonzalez JP, Henwood JM: Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1989) 37:628-668
17. Norrby SR: Side-effects of quinolones: comparisons between quinolones and other antibiotics. European Journal of Clinical Microbiology & Infectious Diseases (1991) 19:378-383
18. Iravani A: Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. American Journal of Medicine (1991) 94, Supplement A: 89-96
19. Stahlmann R: Safety profile of the quinolones. Journal of Antimicrobial Chemotherapy (1990) 26, Supplement D: 31-44
20. Mayne JT, Johnson NJ, Kluwe WM, Lencoski DL, Polzer RJ: A study of the phototoxic potential of trovafloxacin in BALB/c mice. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 51-55
21. Maesen FPV, Teengs JP, Baur C, Davies BI: Quinolones and raised plasma concentrations of theophylline. Lancet (1984) ii: 530
22. Wijnands WJA, VanHerwaarden CLA, Vree T: Enoxacin raises plasma concentrations of theophylline. Lancet (1984) ii: 108-109
23. Wijnands WJA, Vree T, VanHerwaarden CLA: The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology (1986) 22:677-683
24. Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL: Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 81-86